Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
Trial ID or NCT#
NCT00958841,29,30,27555
Status
NOT RECRUITING
Purpose
This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.
Official Title
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rare Tumors of Neuroendocrine Origin
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
- - Male and Female Patients at least 18 years old - Patient who have rare tumors of neuroendocrine origin, such as tumors of the: 1. pancreas 2. pituitary glands 3. Nelson syndrome 4. ectopic-ACTH secreting tumor - Patients who have failed standard of care treatment or for whom no standard of care treatment exist - Signed Informed Consent
Exclusion Criteria:
- - Patients with active gallbladder disease - Patients with any ongoing or planned anti-neoplastic or interferon therapy - Poorly controlled diabetes mellitus - Female patients who are pregnant or lactating, or are of childbearing potential and not practicing a medically acceptable method of birth control Other protocol-defined inclusion/exclusion criteria may apply.
Investigator(s)
Y. Joyce Liao, MD, PhD
Neuro-ophthalmology specialist
Stanford Medicine Professor of Ophthalmology and Professor of Neurology
Contact us to find out if this trial is right for you.
Contact
Cancer Clinical Trials Office
650-498-7061
View on ClinicalTrials.gov
